JP2022537358A5 - - Google Patents
Info
- Publication number
- JP2022537358A5 JP2022537358A5 JP2021575365A JP2021575365A JP2022537358A5 JP 2022537358 A5 JP2022537358 A5 JP 2022537358A5 JP 2021575365 A JP2021575365 A JP 2021575365A JP 2021575365 A JP2021575365 A JP 2021575365A JP 2022537358 A5 JP2022537358 A5 JP 2022537358A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- compound according
- amino
- compound
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962864031P | 2019-06-20 | 2019-06-20 | |
| US62/864,031 | 2019-06-20 | ||
| PCT/US2020/038395 WO2020257429A1 (en) | 2019-06-20 | 2020-06-18 | Ectonucleotidase inhibitors and methods of use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022537358A JP2022537358A (ja) | 2022-08-25 |
| JP2022537358A5 true JP2022537358A5 (enExample) | 2023-06-14 |
Family
ID=74040909
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021575365A Withdrawn JP2022537358A (ja) | 2019-06-20 | 2020-06-18 | エクトヌクレオチダーゼ阻害剤およびその使用方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20220363709A1 (enExample) |
| EP (1) | EP3986894A4 (enExample) |
| JP (1) | JP2022537358A (enExample) |
| KR (1) | KR20220024629A (enExample) |
| CN (1) | CN114008048A (enExample) |
| AU (1) | AU2020294724A1 (enExample) |
| CA (1) | CA3143496A1 (enExample) |
| WO (1) | WO2020257429A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11129841B2 (en) | 2017-05-10 | 2021-09-28 | Oric Pharmaceuticals, Inc. | CD73 inhibitors |
| US11377469B2 (en) | 2017-11-03 | 2022-07-05 | Oric Pharmaceuticals, Inc. | CD73 inhibitors |
| CA3098493A1 (en) | 2018-04-30 | 2019-11-07 | Oric Pharmaceuticals, Inc. | Cd73 inhibitors |
| KR102902754B1 (ko) | 2018-06-21 | 2025-12-19 | 안텐진 테라퓨틱스 리미티드 | 엑토뉴클레오티다제 저해제 및 이의 사용 방법 |
| US12544391B2 (en) | 2019-07-16 | 2026-02-10 | Oric Pharmaceuticals, Inc. | CD73 inhibitors |
| CN116854758A (zh) | 2019-10-30 | 2023-10-10 | 欧瑞克制药公司 | Cd73抑制剂 |
| AU2023252914A1 (en) | 2022-04-13 | 2024-10-17 | Arcus Biosciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
| KR102775989B1 (ko) * | 2022-11-01 | 2025-03-04 | 윤주호 | 콜치신과 메트포르민을 유효성분으로 하는 퇴행성 신경계 질환의 예방 또는 치료용 조성물 |
| US20250230168A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| CN118001265A (zh) * | 2024-03-14 | 2024-05-10 | 哈尔滨医科大学附属第一医院 | 苏拉明在制备减轻心肌梗死后心肌纤维化产品中的应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW528755B (en) * | 1996-12-24 | 2003-04-21 | Glaxo Group Ltd | 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives |
| EP3134411B1 (en) * | 2014-04-25 | 2021-06-30 | Boehringer Ingelheim International GmbH | Purine derivatives as cd73 inhibitors for the treatment of cancer |
| CN110234656B (zh) * | 2016-09-09 | 2023-02-28 | 卡利泰拉生物科技公司 | 外核苷酸酶抑制剂及其使用方法 |
| KR102638592B1 (ko) * | 2016-12-22 | 2024-02-19 | 안텐진 테라퓨틱스 리미티드 | 엑토뉴클레오티다제 억제제 및 이의 용도 |
| KR102902754B1 (ko) * | 2018-06-21 | 2025-12-19 | 안텐진 테라퓨틱스 리미티드 | 엑토뉴클레오티다제 저해제 및 이의 사용 방법 |
-
2020
- 2020-06-18 CA CA3143496A patent/CA3143496A1/en active Pending
- 2020-06-18 CN CN202080045115.6A patent/CN114008048A/zh active Pending
- 2020-06-18 JP JP2021575365A patent/JP2022537358A/ja not_active Withdrawn
- 2020-06-18 US US17/620,508 patent/US20220363709A1/en not_active Abandoned
- 2020-06-18 AU AU2020294724A patent/AU2020294724A1/en not_active Abandoned
- 2020-06-18 EP EP20826073.7A patent/EP3986894A4/en not_active Withdrawn
- 2020-06-18 WO PCT/US2020/038395 patent/WO2020257429A1/en not_active Ceased
- 2020-06-18 KR KR1020227001589A patent/KR20220024629A/ko not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021529172A5 (enExample) | ||
| JP7278359B2 (ja) | Ｓｈｐ２の活性を阻害するための化合物および組成物 | |
| NZ754171A (en) | Ectonucleotidase inhibitors and methods of use thereof | |
| US10336774B2 (en) | N-azaspirocycloalkane substituted N-heteroaryl compounds and compositions for inhibiting the activity of SHP2 | |
| TW202341983A (zh) | 用於降解突變kras蛋白之化合物及其應用 | |
| JP6523303B2 (ja) | Ｓｈｐ２の活性を阻害するための１−ピリダジン／トリアジン−３−イル−ピペラジン／ピペリジン／ピロリジン誘導体およびその組成物 | |
| ES2805232T3 (es) | Compuestos y composiciones para inhibir la actividad de SHP2 | |
| ES2387812T3 (es) | Forma termodinámicamente estable del tosilato BAY 43-9006 | |
| JP2019530669A5 (enExample) | ||
| JP2024531477A5 (enExample) | ||
| JP2017517548A5 (enExample) | ||
| EP3302482A1 (en) | Tank-binding kinase-1 protacs and associated methods of use | |
| JP2012515225A5 (enExample) | ||
| JP2019524852A5 (enExample) | ||
| JP2010524957A5 (enExample) | ||
| JP2018529780A5 (enExample) | ||
| WO2018122168A1 (en) | Combinations of bub1 kinase and parp inhibitors | |
| CA3143496A1 (en) | Ectonucleotidase inhibitors and methods of use thereof | |
| AU2020374208B2 (en) | Novel compound and pharmaceutical composition for prevention or treatment of cancer comprising same | |
| JP2018522838A (ja) | ｍＩＤＨ１阻害剤としてのＮ−メンチルベンズイミダゾール | |
| CN107848985A (zh) | 制备取代的3‑(2‑苯胺基‑1‑环己基‑1h‑苯并咪唑‑5‑基)丙酸衍生物的方法 | |
| JP2022507025A5 (enExample) | ||
| JP7539151B2 (ja) | Ｅｔｂｒ活性化に関連する癌を処置するための重水素化化合物、組成物、および方法 | |
| JP2022544031A5 (enExample) | ||
| TW202330539A (zh) | 用於治療、預防或管理過度增生性病症之化合物、醫藥組合物及方法 |